[Edaily Reporter KIM SAE-MI ] LabGenomics. Co., Ltd.(084650)remains at risk of delisting due to its stock price falling below the minimum requirement. To be removed from the watch list, the stock must maintain a closing price of at least 1,000 won for 21 consecutive trading days.
LabGenomics. Co., Ltd. CI (Photo: LabGenomics. Co., Ltd.) The Korea Exchange announced on the 30th that, as of the close of regular trading today, 36 trading days have passed since LabGenomics. Co., Ltd. was designated as a “monitored stock,” and the company has recorded 24 consecutive trading days with a closing price of 1,000 won or higher.
Previously, on August 13, LabGenomics. Co., Ltd. was designated as a “monitored stock” under Article 53 of the KOSDAQ Market Listing Regulations after its common stock closing price fell below 1,000 won for 30 consecutive trading days.
According to KOSDAQ listing regulations, a company designated as a “monitored stock” due to a stock price falling below the threshold must maintain a closing price of 1,000 won or higher for 45 consecutive trading days within 90 trading days of the designation. Failure to meet this requirement constitutes grounds for delisting.
LabGenomics. Co., Ltd. has currently met this requirement for 24 consecutive trading days. If it maintains a closing price of 1,000 won or higher for the next 21 trading days, it will be removed from the watchlist.
The exchange cautioned, “If the closing price falls below 1,000 won starting on the 46th trading day after being designated as a ‘monitored stock,’ it may constitute grounds for delisting,” adding, “Even if procedures such as a stock split or capital reduction are completed, trading suspension and delisting may still occur in accordance with relevant regulations.”
The slump in the non-investment-grade corporate bond market—which has been centered on BBB-rated bonds this year—is expected to spread to A-rated companies next year. As the burden of issuing corporat…
Amid broader market volatility on Thursday, South Korea’s biopharmaceutical sector lacked a clear directional trend, leaving traditional, profitable pharmaceutical and biotech firms to anchor investor…
A forecast indicates that U.S. production of humanoid robots will reach up to 400,000 units by 2030 and 1.5 million units by 2035. Analysts predict that as the humanoid robot industry moves beyond tec…